These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35084313)

  • 1. Efficacy of intravenous neridronate in transient osteoporosis of the hip.
    D'Alessandro R; Falsetti P; Conticini E; Bardelli M; Baldi C; Gentileschi S; Nicosia A; Al Khayyat SG; Cantarini L; Frediani B
    Clin Exp Rheumatol; 2022 Sep; 40(9):1681-1685. PubMed ID: 35084313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neridronate for transient osteoporosis of the hip in a child.
    Gaggiano C; Bardelli M; Tarsia M; Gentileschi S; Maselli A; Grosso S; Cantarini L; Frediani B
    Osteoporos Int; 2022 Jul; 33(7):1619-1624. PubMed ID: 35106625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study.
    Varenna M; Zucchi F; Failoni S; Becciolini A; Berruto M
    Rheumatology (Oxford); 2015 Oct; 54(10):1826-32. PubMed ID: 25998450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pamidronate in the treatment of transient osteoporosis of the hip.
    Varenna M; Zucchi F; Binelli L; Failoni S; Gallazzi M; Sinigaglia L
    Bone; 2002 Jul; 31(1):96-101. PubMed ID: 12110419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neridronate in osteopenic patients after heart, liver or lung transplant: a multicenter, randomized, double-blind, placebo-controlled study.
    Giannini S; Poci C; Fusaro M; Egan CG; Marcocci C; Vignali E; Cetani F; Nannipieri F; Loy M; Gambino A; Adami G; Braga V; Rossini M; Arcidiacono G; Baffa V; Sella S
    Panminerva Med; 2021 Jun; 63(2):214-223. PubMed ID: 34154321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip.
    Agarwala S; Vijayvargiya M
    Ann Rehabil Med; 2019 Jun; 43(3):314-320. PubMed ID: 31311253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
    Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
    Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of neridronate treatment in elderly women with osteoporosis.
    Cascella T; Musella T; Orio F; Palomba S; Bifulco G; Nappi C; Lombardi G; Colao A; Tauchmanova L
    J Endocrinol Invest; 2005 Mar; 28(3):202-8. PubMed ID: 15952402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.
    Forni GL; Perrotta S; Giusti A; Quarta G; Pitrolo L; Cappellini MD; D'Ascola DG; Borgna Pignatti C; Rigano P; Filosa A; Iolascon G; Nobili B; Baldini M; Rosa A; Pinto V; Palummeri E
    Br J Haematol; 2012 Jul; 158(2):274-282. PubMed ID: 22571408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study.
    Varenna M; Adami S; Rossini M; Gatti D; Idolazzi L; Zucchi F; Malavolta N; Sinigaglia L
    Rheumatology (Oxford); 2013 Mar; 52(3):534-42. PubMed ID: 23204550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone.
    Merlotti D; Rendina D; Gennari L; Mossetti G; Gianfrancesco F; Martini G; De Filippo G; Avanzati A; Franci B; Campagna MS; Strazzullo P; Nuti R
    J Bone Miner Res; 2011 Mar; 26(3):512-8. PubMed ID: 20814970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study.
    Varenna M; Gatti D; Zucchi F; Crotti C; Braga V; Iolascon G; Frediani B; Nannipieri F; Rossini M
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221142274. PubMed ID: 36569491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful neridronate therapy in transient osteoporosis of the hip.
    La Montagna G; Malesci D; Tirri R; Valentini G
    Clin Rheumatol; 2005 Feb; 24(1):67-9. PubMed ID: 15322945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin in the treatment of transient osteoporosis of the hip.
    Arayssi TK; Tawbi HA; Usta IM; Hourani MH
    Semin Arthritis Rheum; 2003 Jun; 32(6):388-97. PubMed ID: 12833247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
    Ringe JD; Dorst A; Faber H
    Osteoporos Int; 2005 Dec; 16(12):2063-8. PubMed ID: 16228105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
    Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient osteoporosis of the hip treated with hyperbaric oxygen therapy: a case series.
    Yagishita K; Jinno T; Koga D; Kato T; Enomoto M; Kato T; Muneta T; Okawa A
    Undersea Hyperb Med; 2016; 43(7):847-854. PubMed ID: 28777523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient Osteoporosis of the Hip: A Mysterious Cause of Hip Pain in Adults.
    Vaishya R; Agarwal AK; Kumar V; Vijay V; Vaish A
    Indian J Orthop; 2017; 51(4):455-460. PubMed ID: 28790475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
    J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.